UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of December 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 19 December 2025, London UK
GSK enters agreement with U.S. government to lower drug prices and
expand access to respiratory medicines for millions of
Americans
●
Voluntary
agreement delivers on all four of President Trump's requests and
reduces the cost of medicines for Americans
●
Includes
products used to treat the more than 40 million patients in the
U.S. who suffer from respiratory conditions such as asthma and
COPD
●
Builds
on GSK's decades-long commitment to make products accessible
worldwide to those who need them
GSK plc (LSE/NYSE: GSK) announced that it has entered into an
agreement with the U.S. Administration to lower the cost of
prescription medicines for American patients, including GSK's broad
respiratory portfolio which is used to treat the more than 40
million Americans who suffer from respiratory conditions such as
asthma and COPD.
The agreement delivers on all four actions requested by President
Trump in his July 31st letter. As part of the agreement, GSK will
lower the price of certain medicines in Medicaid and will launch
new products with a more balanced pricing approach which recognises
the value of innovation across developed nations.
Building on GSK's ongoing global commitment to responsible pricing,
the Company will also make most of its inhaled respiratory
portfolio and other products available to patients on a direct
purchasing platform that will offer savings of up to
66%.
As part of the President's Strategic Active Pharmaceutical
Ingredients Reserve (SAPIR), GSK will further support the
resilience of the U.S. supply chain for critical medicines by
securing for the U.S. a reserve of albuterol (also known as
salbutamol), the active ingredient used in many inhalers to relieve
the symptoms of asthma and COPD.
The agreements entered into cover both GSK and ViiV Healthcare. The
agreements provide clarity to both companies on the future US
pricing framework, and exclude GSK and ViiV from s232 tariffs for 3
years. The detailed terms of the agreements remain
confidential.
GSK CEO Emma Walmsley said: "Today's
announcement builds on GSK's strong track record of
increasing
access and improving the affordability of its medicines worldwide,
including an ongoing commitment to responsible pricing. GSK has
been at the forefront of respiratory innovation for decades -
helping millions of Americans prevent and treat chronic respiratory
diseases such as asthma and COPD. Through this agreement, GSK will
ensure patients have access to the current portfolio of respiratory
medicines while bringing the next wave of innovation to American
patients."
In September 2025, GSK announced plans to invest more than $30bn in
R&D and manufacturing in the
U.S. over the next 5 years. This includes $2bn of new investment
commitments in manufacturing facilities, AI and advanced digital
technologies announced in the past 12 months, creating hundreds of
highly skilled
U.S. jobs.
These investments build on GSK's strong innovation and
manufacturing footprint, capabilities and approximately 15,000
strong U.S. workforce today, developing and making products in the
United States for the United States.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Constantin
Fest
|
+44 (0)
7831 826525
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Sam
Piper
|
+44 (0)
7824 525779
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q3 Results for 2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: December
23, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
